European Respiratory Society guidelines for the management of adult bronchiectasis
- PMID: 28889110
- DOI: 10.1183/13993003.00629-2017
European Respiratory Society guidelines for the management of adult bronchiectasis
Abstract
Bronchiectasis in adults is a chronic disorder associated with poor quality of life and frequent exacerbations in many patients. There have been no previous international guidelines.The European Respiratory Society guidelines for the management of adult bronchiectasis describe the appropriate investigation and treatment strategies determined by a systematic review of the literature.A multidisciplinary group representing respiratory medicine, microbiology, physiotherapy, thoracic surgery, primary care, methodology and patients considered the most relevant clinical questions (for both clinicians and patients) related to management of bronchiectasis. Nine key clinical questions were generated and a systematic review was conducted to identify published systematic reviews, randomised clinical trials and observational studies that answered these questions. We used the GRADE approach to define the quality of the evidence and the level of recommendations. The resulting guideline addresses the investigation of underlying causes of bronchiectasis, treatment of exacerbations, pathogen eradication, long term antibiotic treatment, anti-inflammatories, mucoactive drugs, bronchodilators, surgical treatment and respiratory physiotherapy.These recommendations can be used to benchmark quality of care for people with bronchiectasis across Europe and to improve outcomes.
Copyright ©ERS 2017.
Conflict of interest statement
Conflict of interest: D. Rigau and T. Tonia act as methodologists for the European Respiratory Society. All other disclosures can be found alongside this article at erj.ersjournals.com
Comment in
-
Macrolides, mucoactive drugs and adherence for the management of bronchiectasis.Eur Respir J. 2018 Jan 4;51(1):1701987. doi: 10.1183/13993003.01987-2017. Print 2018 Jan. Eur Respir J. 2018. PMID: 29301925 No abstract available.
-
Macrolides, mucoactive drugs and adherence for the management of bronchiectasis.Eur Respir J. 2018 Jan 4;51(1):1702033. doi: 10.1183/13993003.02033-2017. Print 2018 Jan. Eur Respir J. 2018. PMID: 29301926 No abstract available.
Similar articles
-
European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis.Eur Respir J. 2021 Aug 26;58(2):2002990. doi: 10.1183/13993003.02990-2020. Print 2021 Aug. Eur Respir J. 2021. PMID: 33542057
-
Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults.NPJ Prim Care Respir Med. 2017 Mar 13;27(1):18. doi: 10.1038/s41533-017-0019-9. NPJ Prim Care Respir Med. 2017. PMID: 28270656 Free PMC article. Review.
-
Management of bronchiectasis and chronic suppurative lung disease in indigenous children and adults from rural and remote Australian communities.Med J Aust. 2008 Oct 6;189(7):386-93. doi: 10.5694/j.1326-5377.2008.tb02085.x. Med J Aust. 2008. PMID: 18837683
-
Primary care implications of the British Thoracic Society Guidelines for bronchiectasis in adults 2019.NPJ Prim Care Respir Med. 2019 Jun 27;29(1):24. doi: 10.1038/s41533-019-0136-8. NPJ Prim Care Respir Med. 2019. PMID: 31249313 Free PMC article. Review.
-
European Respiratory Society statement for defining respiratory exacerbations in children and adolescents with bronchiectasis for clinical trials.Eur Respir J. 2022 Nov 3;60(5):2200300. doi: 10.1183/13993003.00300-2022. Print 2022 Nov. Eur Respir J. 2022. PMID: 35728974
Cited by
-
Exacerbations of bronchiectasis.Eur Respir Rev. 2024 Jul 24;33(173):240085. doi: 10.1183/16000617.0085-2024. Print 2024 Jul. Eur Respir Rev. 2024. PMID: 39048130 Free PMC article. Review.
-
The Establishment of China Bronchiectasis Registry and Research Collaboration (BE-China): Protocol of a prospective multicenter observational study.Respir Res. 2022 Dec 3;23(1):328. doi: 10.1186/s12931-022-02254-9. Respir Res. 2022. PMID: 36463140 Free PMC article.
-
Bronchodilators in bronchiectasis: we urgently need more trials.Lung. 2023 Feb;201(1):5-7. doi: 10.1007/s00408-023-00600-2. Epub 2023 Feb 7. Lung. 2023. PMID: 36746814 No abstract available.
-
Increasing prevalence and burden of bronchiectasis in urban Chinese adults, 2013-2017: a nationwide population-based cohort study.Respir Res. 2022 May 4;23(1):111. doi: 10.1186/s12931-022-02023-8. Respir Res. 2022. PMID: 35509081 Free PMC article.
-
Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial.Lancet Respir Med. 2019 Sep;7(9):791-801. doi: 10.1016/S2213-2600(19)30254-1. Epub 2019 Aug 16. Lancet Respir Med. 2019. PMID: 31427252 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical